Share this article on:

Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals

Brindeiro, Rodrigo Ma; Diaz, Ricardo Sb; Sabino, Ester Cc; Morgado, Mariza Gd; Pires, Ivone Le,f; Brigido, Luísg; Dantas, Maria Ch; Barreira, Draurioh; Teixeira, Paulo Rh; Tanuri, Amilcaraand the Brazilian Network for Drug Resistance Surveillance


Objective: To study the prevalence of HIV drug resistance mutations and subtype distribution in a Brazilian drug-naive population. Asymptomatic, drug-naive HIV-1-infected individuals were targeted in 13 voluntary counseling and testing centers spread around the country.

Methods: Plasma viral RNA was extracted from 535 HIV-1-positive subjects. Protease (PR) and reverse transcriptase (RT) genomic regions were sequenced for subtype determination and analysis of drug resistance mutations.

Results: Eight samples (2.24 %) showed primary mutations related to protease inhibitor (PI) resistance, eight (2.36%) to nucleoside reverse transcriptase inhibitors (NRTI) and seven (2.06%) to non-nucleoside reverse transcriptase inhibitors (NNRTI). Accessory mutations were found in the PR gene at the following positions: L63P/V/T/A/I [153/345 (44.3%)], M36I/L [149/345 (43.2%)], L10I/F/V [82/345 (23.8%)], V77I [60/345 (17.4%)], A71V/T [11/345 (3.2%)], K20M/R [10/345 (2.9%)], and V82I [4/345 (1.2%)]. Mutations known to be associated with reduced sensitivity to NRTI or NNRTI (V118I, E44D, K219R, T69A, and V75L) were found in a low prevalence (0.6–2.4%). A high proportion of the isolates from subtype C was found in the southern states. Subtype F-related viruses were the main non-B variant in the rest of the country.

Conclusions: Brazil has a low prevalence of drug-resistant strains circulating among recently diagnosed individuals. However, there was an increase in these rates compared with similar studies performed with samples collected in Brazil from 1996 to 1998. Continued surveys are required to detect trends in these rates, but routine genotypic testing in the drug-naive population prior to antiretroviral initiation is not required in Brazil.

From the aLaboratory of Molecular Virology, the Department of Genetics and the bInstitute of Microbiology Prof. Paulo Góes, Federal University of Rio de Janeiro, the cDepartment of Imunology, Foundation Institute Oswaldo Cruz, and the dLaboratory of Virology, Institute of Biology do Exército, Rio de Janeiro, the eLaboratory of Retrovirology, Paulista School of Medicine/UNIFESP, the fFoundation Pro-Sangue, Hemocentro de São Paulo, University of São Paulo and the gLaboratory of Retrovirology, Institute Adolfo Lutz, São Paulo, and hCN-DST/AIDS, Ministry of Health, Brasília, Brazil. *See the Appendix for other members of HIV-BResNeT.

Requests for reprints to: Dr A. Tanuri, Laboratório de Virologia Molecular, Departamento de Genética, Universidade Federal do Rio de Janeiro, CCS–Bloco A–Cidade Universitária–Ilha do Fundão, 21944-970 Rio de Janeiro, RJ, Brazil.

Received: 1 August 2002; revised: 22 November 2002; accepted: 29 November 2002.

Back to Top | Article Outline


The development of drug resistance remains one of the most serious obstacles to sustained suppression of HIV during highly active antiretroviral therapy (HAART) [1–7].

In developed countries the prevalence of transmission of viruses that are resistant to one or more antiretroviral agent has increased in recent years. The range of reported rates among recent seroconverters includes 5–11% in Switzerland [8,9], 10–17% in France [10,11], 13% in German [12], 14% in the United Kingdom [13], 15–26% in North America [14–16], 23–26% in Spain [17–19], 5–7% in the Unite States [20,21], and 15.4% in Argentina [22]. Mutations associated with resistance to nucleoside reverse transcriptase inhibitors (NRTI), especially zidovudine and lamivudine, are the most prevalent among drug-naive HIV-infected patients. The prevalence of HIV strains with at least one primary drug- resistant mutation in Africa, South America and the Caribbean is low (less than 7%), and the frequency of accessory mutations is high (up to 90%) [23–26].

Prevalence rates for HIV/AIDS in Brazil are approximately 0.6% of the population (Brazilian Ministry of Health, Brazil has shown a constant change in the character of its HIV-1 epidemic regarding gender infection ratio and risk behavior. Since the beginning of the epidemic, HIV infection patterns have shifted towards women and heterosexuals. The country's HIV-1 subtype profile includes the major circulating subtype B of HIV-1 but other subtypes, such as F, C and B/C and B/F divergent sequences, co-circulate [27–31].

The Brazilian Ministry of Health has been sponsoring a policy of universal access to antiretroviral drugs for AIDS patients since 1996. In order to monitor the transmission of drug-resistant strains and the subtype profile in Brazil, a National Network for Drug Resistance Surveillance (HIV-BResNet) in the drug-naive population was established. This work shows genotypic analysis from asymptomatic, drug-naive HIV-1-infected individuals diagnosed in 13 voluntary counseling and testing centers in different regions of the country in 2001.

Back to Top | Article Outline



Plasma from 535 consecutive HIV-1-positive individuals confirmed by serology was isolated at different voluntary counseling and testing centers of the Brazilian Ministry of Health. The collection period was 3 months to avoid resampling. These sites spanned metropolitan regions located in eight different Brazilian states, Rio Grande do Sul (n = 139), Paraná (n = 147), São Paulo (n = 100), Rio de Janeiro (n = 83), Mato Grosso do Sul (n = 7), Pará (n = 17), Bahia (n = 12), and Ceará (n = 30), that covered 45% of Brazilian patients taking HAART. None of the subjects has ever been exposed to any antiretroviral treatment according to their written statement. The study was approved by the Brazilian IRB (project 526–CONEP) as an anonymous unlinked study.

Back to Top | Article Outline

RNA isolation, amplification and sequencing

Virus RNA was isolated as previously described [32]. Following complimentary DNA generation with random primers, nested polymerase chain reactions (PCR) was conducted for individual amplification of protease (PR, whole region) and reverse transcriptase (RT, nucleotides 105–651) [32,33]. PCR fragments were sequenced in an ABI 310 automated sequencer (Applied Biosystems, Foster City, California, USA). All sequences obtained were subjected to quality control assessments to ensure that there were no sample mix-ups or contamination from other sources [34].

Back to Top | Article Outline

Phylogenetic and sequence analyses

PR and RT sequences from all samples were submitted to phylogenetic analysis for HIV-1 subtype determination. Sequences were aligned using ClustalW [35,36] against the reference set for subtyping analysis from the Los Alamos database ( Phylogenetic inferences were performed by the neighbor-joining method using the F84 model of substitution implemented in PAUP v. 4.0b2a [37]. In order to study the drug resistance mutations, sequences were translated and aligned. The positions related to HIV drug resistance previously reported [38,39] were manually inspected and scored. The differential incidences of subtypes and resistance, and their association with epidemiological data, were statistically evaluated using a two-tailed Fisher exact test.

Back to Top | Article Outline


Table 1 summarizes all relevant epidemiological data of the individuals analyzed. There were 126 samples (23.6%) that did not generate PCR fragments for either genomic region (PR or RT) and these were excluded from the analysis. The epidemiological data shows nearly an identical sex ratio (male to female ratio of 1.45) among samples.

Table 1

Table 1

Eight samples (2.24 %) showed primary mutations related to PI resistance, eight (2.36%) to NRTI, and seven (2.06%) to non-nucleoside reverse transcriptase inhibitors (NNRTI). No individuals were found carrying primary mutations for more than one class of antiretroviral drugs, except for sample SP653 (Table 2). When individuals carrying primary mutations in the RT and PR regions were stratified in different geographical areas, there were no clusters of mutation prevalence in any particular area, except for PI, which was not found in the northern states. There was no significant association between the presence of resistant genotypes in the individuals studied and the sexual partner's reported HIV serostatus (P = 0.4552) or use of antiretroviral drugs (P = 0.2696).

Table 2

Table 2

In contrast to the low prevalence of primary mutations to drug resistance, many accessory mutations were found in PR gene, with high prevalence at the following positions: L63P/V/T/A/I [153/345 (44.3%)], M36I/L [149/345 (43.2%)], L10I/F/V [82/345 (23.8%)], V77I [60/345 (17.4%)], A71V/T [11/345 (3.2%)], K20M/R [10/345 (2.9%)], and V82I [4/345 (1.2%)] There was a clear association of accessory substitutions L63P and M36I with subtype assignment. The first one was associated with B subtype whereas the second was clearly associated with subtypes F and C.

The same type of analysis was performed for the RT deduced amino acid sequences. At the positions known to be associated with reduced sensitivity to commonly used NRTI or NNRTI [38,39], 8/327 had the V118I mutation (2.4%), 4/327 had E44D (1.2%), and 4/327 had K219R (1.2%).

A map of the Brazilian territory showing the distribution of subtypes found in our dataset is depicted in Fig. 1. We have identified 231 (64.9%) and 212 (62.5%) subtype B, 81(22.8%) and 100 (29.5%) subtype C, and 42 (11.8%) and 27 (8%) subtype F viruses based on PR and RT genomic regions, respectively. When both genomic regions were analyzed simultaneously, 42 sequences showed evidence of subtype divergence between two of those subtypes, such as PR C/RT B, PR B/RT C, PR B/RT F, PR F/RT B, PR C/RT F, and PR F/RT C. These divergent genomes together represented 14.48% of the total samples analyzed in both regions.

Fig. 1.

Fig. 1.

Back to Top | Article Outline


A low prevalence of primary drug-resistant mutations was observed in HIV-1 variants from the HIV-positive individuals diagnosed in Brazilian voluntary counseling and testing centers in 2001, indicating a low occurrence (4.42% for NRTI and NNRTI, and 2.24% for PI) of resistant strains circulating in drug-naive subjects. These results contrast with the ones originated from samples collected in the country until 1998 [40–43], in which a low prevalence (2%) of isolates carrying genotypic resistance was found. However, our findings are in accordance with the proportion of drug-naive subjects infected with drug-resistant viruses identified in studies from other Latin American countries [44,45] and Africa [23,24]. Many reports suggest no increase [11,15,20,46,47], while others show increase [12–14, 17,18,44,45] or even a decrease [9] in the prevalence of transmission of these resistant variants. However, studies conducted in Europe [8–14,16,18,48] and in North America [14–16,47,49–51] have reported the transmission of drug-resistant variants in up to 10 to 25% of subjects with primary HIV infection and in 5 to 17% of therapy-naive subjects. Although the dates of first diagnosis of HIV infection and sample collection are the same in our study, we cannot exclude the possible reversion of transmitted drug-resistant mutants to wild-type viruses since primary infection. However, although our data may underestimate the true prevalence of primary antiretroviral drug resistance, the persistence of transmitted or acquired drug-resistant mutations in the absence of selective drug pressure has been demonstrated [23,25,44,45,47,52].

The presence of multiple PR accessory mutations can reduce the genetic barrier and yield a faster selection of resistant strains when compared with the wild type isolates. Recent data suggest that some of the polymorphic mutations at positions 10, 36, 63, 71, and 77 in PR can be associated with therapeutic failure in naive or therapy-experienced patients [53]. We could also find some individuals carrying viruses showing mutations such as V106I and V108I, previously implicated in intermediate levels of phenotypic resistance to NNRTI drugs [38,39]. Phenotypic resistance to NNRTI from 4- to 10-fold to wild-type reference strains were not associated with the virological outcome of therapeutic regimens containing these drugs [54].

A large proportion of HIV-1 subtype C in the south of Brazil was observed. Previous surveys in Brazil have shown frequencies of around 3% for subtype C viruses in the country [27,55]. We have found that almost 30% of the viruses circulating in southern Brazil are of subtype C. We can speculate an increase in the prevalence of C subtype in southern cities. This high prevalence of subtype C samples decreases northbound: the prevalence was 24% in Paraná state and 3% in São Paulo state. Subtype F variant is spread all over the country and corresponds approximately to 10% of the samples analyzed in Rio de Janeiro and São Paulo cities. Recently, several groups have reported the appearance of recombinant forms of subtype B and F. In fact, in our dataset, the prototypic F strains are in low numbers compared with the divergent subtype genome counterparts carrying F sequences [40]. Our data support previous findings showing a wide geographical spread of prototypic and divergent subtype forms of subtype F isolates. Clade C-related strains decrease northbound, clade F-related viruses increase towards the north and the center of the country (Fig. 1).

The isolates’ subtype assignment could not be correlated with risk factors or primary mutations. However, a significant correlation was observed between the subtype C isolates and gender in the southern region sites. These variants were found preferentially in women (P < 0.0026), with a sex ratio (male to female) 0.89; this compares with a ratio of 2.45 for subtype B viruses. This observation can be linked to the recent introduction of this subtype in this geographic region concomitant with the feminization of the epidemic in Brazil. Similarly, there was a tendency to find subtype C isolates in individuals reporting heterosexual practice as a risk factor (P < 0.112).

Although recent reports suggest that genotypic resistance testing has a significant benefit in predicting virological response to alternative therapy for patients showing virological failure [56], no data exist to support the routine use of resistance testing in drug-naive patients beginning therapy. The findings reported in our study do not suggest the need for routine genotypic testing in the drug-naive population. However, epidemiological monitoring of the prevalence of primary resistance must be implemented on a routine basis in countries with widespread availability of HAART.

Back to Top | Article Outline


All members of HIV-BResNet equally contributed to this study.

Sponsorship: This study was supported by the AIDS/STD National Program, Brazilian Ministry of Health, the State Science Foundation of Rio de Janeiro Grant E-26/151.970/00, the Brazilian Council for Scientific and Technologic Development Grant 462394/00-0, and Fundação de Amparo e Pesquisa de São Paulo Grant 98/14381-4.

Back to Top | Article Outline


1.Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998, 280:78–86.
2.Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998, 128:906–911.
3.Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863–868.
4.Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295–1300.
5.Ross L, Johnson M, DeMasi R, Liao Q, Graham N, Shaefer M, et al. Viral genetic heterogeneity in HIV-1 infected individuals is associated with increasing use of HAART and higher viremia. AIDS 2000, 14:813–819.
6.Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, et al. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001, 15:1269–1274
7.Vella S. and Palmisano L. Antiviral therapy: state of the HAART. Antiviral Res 2000, 45:1–7.
8.Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354:729–733.
9.Yerly S, Race E, Vora S, Rizzardi P, Chave JP, Flepp M, et al. HIV drug resistance and molecular epidemiology in patients with primary HIV infection. In Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 754].
10.Chaix ML, Harzic M, Masquelier B, Pellegrin I, Meyer L, Costagliola D, et al. Prevalence of genotypic drug resistance among French patients infected during the year 1999. In Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 755].
11.Tamalet C, Pasquier C, Yahi N, Colson P, Martin LP, Lepeu G, et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 2000, 61:181–186.
12.Duwe S, Brunn M, Altman D, Hamouda O, Schmidt B, Walter H, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients from the German seroconverter study. J Acquir Immune Defic Syndr 2001, 26:266–273.
13.UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Br Med J 2001, 322:1087–1088.
14.Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. Antiviral Ther 2001, 6(suppl 1):21.
15.Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999, 282:1135–1141.
16.Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999, 131:502–506.
17.Briones C, Perez-Olmeda M, Rodriguez C, Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001, 26:145–150.
18.Puig T, Perez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 2000, 14:727–732.
19.Gomez-Cano M, Rubio A, Puig T, Perez-Olmeda M, Ruiz L, Soriano V, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998,12:1015–1020.
20.Weinstock H, Respess R, Heneine W, Petropoulos CJ, Hellmann NS, Luo CC, et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconversters in the United States, 1993–1998. J Infect Dis 2000, 182:330–333.
21.Zaidi I, Weinstock H, Woods T, Petropoulos CJ, Hellmann NS, Luo CC, et al. Prevalence of mutations associated with antiretroviral drug resistance among HIV-1-infected persons in 10 US cities, 1997–2000. Antiviral Ther 2001, 6(suppl 1):118.
22.Kijak GH, Pampuro SE, Avila MM, Zala C, Cahn P, Wainberg MA, Salomon H. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antiviral Ther 2001, 6:71–77.
23.Cesaire R, Dos Santos G, Abel S, Bera O, Sobesky G, Cabie A. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies. J Acquire Immune Defic Syndr 1999, 22:401–405.
24.Delgado E, Leon-Ponte M, Villahermosa ML, Cuevas MT, Deibis L, Echeverria G, et al. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: A UNAIDS study. AIDS Res Hum Retroviruses 2001, 17:753–758.
25.Becker PG, Mellquist JL, Guay L, Mmiro F, Ndugwa C, Kataaha P, et al. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retroviruses 2000, 16:807–813.
26.Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000, 38:3919–3925.
27.Bongertz V, Bou-Habib DC, Brigido LF, Caseiro M, Chequer PJ, Couto-Fernandez JC, et al. HIV-1 diversity in Brazil: genetic, biologic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites. J Acquir Immune Defic Syndr 2000, 23:184–193.
28.Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, et al. Drug-resistance reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virology 2000, 275:107–115.
29.Cornelissen M, Kampinga G, Zorgdrager F, for the UNAIDS Network for HIV Isolation and Characterization. Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. J Virol 1996, 70:8209–8212.
30.Couto-Fernandez JC, Morgado MG, Bongertz V, Tanuri A, Andrade T, Brites C, et al. HIV-1 subtyping in Salvador, Bahia, Brazil: a city with African sociodemographic characteristics. J Acquir Immune Defic Syndr 1999, 22:288–293.
31.Sabino EC, Shpaer EG, Morgado MG, Korber BT, Diaz RS, Bongertz V, et al. Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol 1994, 68:6340–6346.
32.Tanuri A, Vicente AC, Otsuki K, Ramos CA, Ferreira OC Jr, Schechter M, et al. Genetic variation and susceptibilities to protease inhibitors among subtypes B and F isolates in Brazil. Antimicrob Agents Chemother 1999, 43:253–258.
33.Stuyver L, Wyseur A, Rombout A, Lowagie J, Scarcez T, Verhofstede C, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997, 41:284–291.
34.Gaschen B, Kuiken C, Korber B, Foley F. Retrieval and on-the-fly alignment of sequence fragments from the HIV database. Bioinformatics 2001, 17:415–418.
35.Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994, 22:4673–4680.
36.Smith SW, Overbeek CR, Woese W, Gilbert W, Gillevet PM. The genetic data environment: an expandable GUI for multiple sequence analysis. Comput Appl Biosci 1994, 10:671–675.
37.Swofford D. PAUP 4.0: Phylogenetic Analysis using Parsimony (and Other Methods), 4.0b2a. Sunderland, MA: Sinauer; 1999.
38.Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000, 283:2417–2426.
39.Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998, 279:1984–1991.
40.Ramos A, Tanuri A, Schechter M, Rayfield MA, Hu DJ, Cabral MC, et al. Dual and recombinant infections: an integral part of the HIV-1 epidemic in Brazil. Emerg Infect Dis 1999, 5:65–74.
41.Pieniazek D, Peralta JM, Ferreira JA, Krebs JW, Owen SM, Sion FS, et al. Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction. AIDS 1991, 5:1293–1299.
42.Potts KE, Kalish ML, Lott T, Orloff G, Luo CC, Bernard MA, et al. Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. AIDS 1993, 7:1191–1197.
43.Tanuri A, Swanson P, Devare S, Berro OJ, Savedra A, Costa LJ, et al. HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:60–66.
44.Tambussi G, Boeri E, Carrera P, Gianotti N, Lazzarin A. Prevalence of mutation associated with resistance to nucleoside analogues in a cohort of naive HIV-1 positive subjects during the period 1984–1997. J Biol Regu. Homeost Agents 1998, 12(suppl 1–2):32–34.
45.Dietrich U, Raudonat I, Wolf E, Jager H, Husak R, Orfanos CE, et al. Indication for increasing prevalence of resistance mutations for protease inhibitors in therapy-naive HIV-1-positive German patients. AIDS 1999, 13:2304–2305.
46.van Vaerenbergh K, Debaisieux L, de Cabooter N, Declercq C, Desmet K, Fransen K, et al. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1 infected patients in Belgium. Antiviral Ther 2001, 6:63–70.
47.Little SJ, Daar ES, D`Aquila RT, Keiser, PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999, 282:1142–1149.
48.Trabaud MA, Leriche KG, Corinne R, Keiser PH, Connick E, Whitcomb JM, et al. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: High proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus. J Med Virol 2000, 61:352–359.
49.Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000, 14:F17–F23.
50.Brenner B, Wainberg MA, Salomon H, Rouleau D, Dascal A, Spira B, et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Int J Antimicrob Agents 2000, 16: 429–434.
51.Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385–394.
52.Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. AIDS 2000, 14:1–7.
53.Frater J, Dunn D, Weber JN, McClure MO. Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome. J Infect Dis. 2002,185:1376.
54.Clevenbergh P, Cua E, Dam E, Durant J, Schmit JC, Boulme R, et al. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV-infected patients. HIV Clin Trials 2002, 3: 36–44
55.Osmanov S, Heyward WL, Esparza J and the World Health Organization Network for HIV Isolation and Characterization. Summary of a pilot study. AIDS Res Hum Retroviruses 1994 10:1325–1326.
56.Durant J, Clevenberg P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353: 2195–2199.
Back to Top | Article Outline


Other members of HIV-BResNet: M. A. Soares, M. Arruda, P. A. Brindeiro, A. Afonso, E. Soares (UFRJ, Rio de Janeiro); E. Caride (BioManguinhos, FIOCRUZ), F. A. B. Speranza, S. Ishii (IBEX, Rio de Janeiro); S. Chequer-Fernandez, J. C. Couto-Fernandez (FIOCRUZ, Rio de Janeiro); E. Cavalieri, L. Costa (EPM/UNIFESP, São Paulo); A. S. Nishiya N. Gaburo (Fundação Pró-Sangue, São Paulo); R. Rodriges, R. Custódio (Instituto Adolfo Lutz, São Paulo); C. Lauria (Lab Ac. Nucleicos, HPE, UERJ, Rio de Janeiro). Contributors from voluntary counseling and testing centers in alphabetical order: Cristina Caliento, Ana M. S. Cavalcanti, Vera M. S. Costa, Maria A. Daher, Maria I. Espineli, Rosa M. C. Ferreira, Cecília K. Kanashiro, Maria E. F. P. Magalhães, Jaciléia M. Pereira, Cristiane M. S. Quadros, Célia F. R. Queiroz, Carlos A. Silva, Marta da-S. Soares, Maria A. A. S. C. Soidan, Isete M. Stela, Jahiel M. de-S. Tavares, Paulete S. Zular.


drug resistance; genotyping; HIV surveillance

© 2003 Lippincott Williams & Wilkins, Inc.